CN1989122B - 新型环戊[b]苯并呋喃衍生物及其用途 - Google Patents
新型环戊[b]苯并呋喃衍生物及其用途 Download PDFInfo
- Publication number
- CN1989122B CN1989122B CN2005800241153A CN200580024115A CN1989122B CN 1989122 B CN1989122 B CN 1989122B CN 2005800241153 A CN2005800241153 A CN 2005800241153A CN 200580024115 A CN200580024115 A CN 200580024115A CN 1989122 B CN1989122 B CN 1989122B
- Authority
- CN
- China
- Prior art keywords
- group
- amino
- hydrogen
- alkylamino
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C**(C=CC1)C=CC1(C)C1(C(CC2=O)C3=CC=C*(*=C)C=C3)Oc3cc(O*)cc(O*)c3C12O Chemical compound C**(C=CC1)C=CC1(C)C1(C(CC2=O)C3=CC=C*(*=C)C=C3)Oc3cc(O*)cc(O*)c3C12O 0.000 description 6
- JHUBNQSPUZXGKI-UHFFFAOYSA-N CC(C)c1ccc2OCOc2c1 Chemical compound CC(C)c1ccc2OCOc2c1 JHUBNQSPUZXGKI-UHFFFAOYSA-N 0.000 description 2
- KSZQPPXGHMWMNR-UHFFFAOYSA-N CCOc1ccc(C(C(c(cc2)ccc2Cl)O2)=O)c2c1 Chemical compound CCOc1ccc(C(C(c(cc2)ccc2Cl)O2)=O)c2c1 KSZQPPXGHMWMNR-UHFFFAOYSA-N 0.000 description 1
- ASCAVGODMXTAFA-UHFFFAOYSA-N CCOc1cccc(OC(C(OC)=O)c(cc2)ccc2Cl)c1 Chemical compound CCOc1cccc(OC(C(OC)=O)c(cc2)ccc2Cl)c1 ASCAVGODMXTAFA-UHFFFAOYSA-N 0.000 description 1
- PBHVDLMCVNHKGV-VHXCZSFDSA-N N[C@H](C[C@H]([C@]1(c(cc2)ccc2Cl)Oc2c3ccc(OCCCl)c2)c2ccccc2)[C@]13O Chemical compound N[C@H](C[C@H]([C@]1(c(cc2)ccc2Cl)Oc2c3ccc(OCCCl)c2)c2ccccc2)[C@]13O PBHVDLMCVNHKGV-VHXCZSFDSA-N 0.000 description 1
- HOEPIYDRIMZBGM-UHFFFAOYSA-N O=C1c(ccc(OCCCl)c2)c2OC1c(cc1)ccc1Cl Chemical compound O=C1c(ccc(OCCCl)c2)c2OC1c(cc1)ccc1Cl HOEPIYDRIMZBGM-UHFFFAOYSA-N 0.000 description 1
- VBQQNLGDDWSWDF-AMEOFWRWSA-N O[C@@H](C[C@H]([C@]1(c(cc2)ccc2Cl)Oc2c3ccc(OCCCN4CCC4)c2)c2ccccc2)[C@]13O Chemical compound O[C@@H](C[C@H]([C@]1(c(cc2)ccc2Cl)Oc2c3ccc(OCCCN4CCC4)c2)c2ccccc2)[C@]13O VBQQNLGDDWSWDF-AMEOFWRWSA-N 0.000 description 1
- NNHXPSFMBCPKGN-VNNZRSTGSA-N O[C@@H](C[C@H]([C@]1(c(cc2)ccc2Cl)Oc2c3ccc(OCCNC4CC4)c2)c2ccccc2)[C@]13O Chemical compound O[C@@H](C[C@H]([C@]1(c(cc2)ccc2Cl)Oc2c3ccc(OCCNC4CC4)c2)c2ccccc2)[C@]13O NNHXPSFMBCPKGN-VNNZRSTGSA-N 0.000 description 1
- SWGWJFIUENXAGI-MCWSDJLFSA-N O[C@H](C[C@H]([C@]1(c(cc2)ccc2Cl)Oc2c3c(OCCCl)ccc2)c2ccccc2)[C@]13O Chemical compound O[C@H](C[C@H]([C@]1(c(cc2)ccc2Cl)Oc2c3c(OCCCl)ccc2)c2ccccc2)[C@]13O SWGWJFIUENXAGI-MCWSDJLFSA-N 0.000 description 1
- MYRIPGAIPCIRRV-OWAUWMPXSA-N O[C@]1(C(C[C@H]2c3ccccc3)=O)c(c(OCCCl)ccc3)c3O[C@]12c(cc1)ccc1Cl Chemical compound O[C@]1(C(C[C@H]2c3ccccc3)=O)c(c(OCCCl)ccc3)c3O[C@]12c(cc1)ccc1Cl MYRIPGAIPCIRRV-OWAUWMPXSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004024504A DE102004024504A1 (de) | 2004-05-18 | 2004-05-18 | Neue Cylopenta[b]benzofuran-Derivate und ihre Verwendung |
DE102004024504.5 | 2004-05-18 | ||
PCT/EP2005/005298 WO2005113529A2 (de) | 2004-05-18 | 2005-05-14 | Neue cylopenta[b]benzofuran-derivate und ihre verwendung |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1989122A CN1989122A (zh) | 2007-06-27 |
CN1989122B true CN1989122B (zh) | 2013-07-24 |
Family
ID=35207782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005800241153A Expired - Fee Related CN1989122B (zh) | 2004-05-18 | 2005-05-14 | 新型环戊[b]苯并呋喃衍生物及其用途 |
Country Status (14)
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8013006B2 (en) | 2004-07-14 | 2011-09-06 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
EP1693059A1 (en) * | 2005-02-22 | 2006-08-23 | Deutsches Krebsforschungszentrum | Use of rocaglamide derivatives as NF-AT-specific inhibitors for the treatment of certain inflammatory diseases |
EP2189453A1 (en) * | 2008-11-25 | 2010-05-26 | Université Louis Pasteur | Rocaglaol derivatives as cardioprotectant agents |
EP2457907A1 (en) * | 2010-11-16 | 2012-05-30 | Université de Strasbourg | Flavagline derivatives as neuroprotective agents |
WO2013016658A1 (en) * | 2011-07-27 | 2013-01-31 | The Ohio State University Research Foundation | Silvestrol, silvestrol analogs and uses thereof |
FR3023290B1 (fr) * | 2014-07-04 | 2016-08-19 | Pf Medicament | Derives de flavaglines |
FI3888658T3 (fi) | 2015-11-25 | 2024-03-22 | Effector Therapeutics Inc | eIF4A:ta inhiboivia yhdisteitä ja niihin liittyviä menetelmiä |
EP3639820A1 (en) * | 2018-10-16 | 2020-04-22 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | Flavagline derivatives for inhibition of kras oncogene activation |
CN110646616B (zh) * | 2019-09-05 | 2023-05-30 | 桂林理工大学 | 一种检测血清中人cTnI的超敏荧光猝灭免疫传感器及检测方法 |
CN110776486B (zh) * | 2019-10-23 | 2022-05-20 | 中国药科大学 | 一种苯并呋喃类小分子p2y14受体抑制剂,及其制备和应用 |
AU2022340664A1 (en) | 2021-09-01 | 2024-03-14 | KHR Biotec GmbH | Novel ras inhibitors |
CN115385924B (zh) * | 2022-10-06 | 2023-10-13 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 一种具有抗肿瘤活性的环戊烷苯并呋喃类化合物及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6420393B1 (en) * | 1998-08-05 | 2002-07-16 | Bayer Aktiengesellschaft | Cyclopentabenzofuran derivatives and their use |
US6518274B1 (en) * | 1998-08-05 | 2003-02-11 | Bayer Aktiengesellschaft | Use of cyclopentabenzofuran-derivatives for combating (NF-κB)-dependent diseases |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19934952A1 (de) * | 1998-07-30 | 2000-02-03 | Novartis Ag | Cyclopentabenzofuran-Derivate |
DE10158561A1 (de) * | 2001-11-29 | 2003-06-12 | Bayer Ag | Neue Verwendung von Cyclopentabenzofuranen |
-
2004
- 2004-05-18 DE DE102004024504A patent/DE102004024504A1/de not_active Withdrawn
-
2005
- 2005-05-14 RU RU2006144710/04A patent/RU2415847C9/ru not_active IP Right Cessation
- 2005-05-14 EP EP05747405A patent/EP1751127B1/de not_active Not-in-force
- 2005-05-14 JP JP2007517059A patent/JP2007538031A/ja active Pending
- 2005-05-14 AU AU2005245104A patent/AU2005245104B2/en not_active Ceased
- 2005-05-14 WO PCT/EP2005/005298 patent/WO2005113529A2/de active Application Filing
- 2005-05-14 CN CN2005800241153A patent/CN1989122B/zh not_active Expired - Fee Related
- 2005-05-14 CA CA2567404A patent/CA2567404C/en not_active Expired - Fee Related
- 2005-05-14 US US11/596,907 patent/US8030347B2/en not_active Expired - Fee Related
- 2005-05-14 MX MXPA06013182A patent/MXPA06013182A/es active IP Right Grant
- 2005-05-14 BR BRPI0510403-3A patent/BRPI0510403A/pt not_active IP Right Cessation
-
2006
- 2006-11-14 IL IL179257A patent/IL179257A/en not_active IP Right Cessation
- 2006-11-14 ZA ZA200609444A patent/ZA200609444B/en unknown
- 2006-11-17 KR KR1020067024170A patent/KR101215164B1/ko not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6420393B1 (en) * | 1998-08-05 | 2002-07-16 | Bayer Aktiengesellschaft | Cyclopentabenzofuran derivatives and their use |
US6518274B1 (en) * | 1998-08-05 | 2003-02-11 | Bayer Aktiengesellschaft | Use of cyclopentabenzofuran-derivatives for combating (NF-κB)-dependent diseases |
Non-Patent Citations (2)
Title |
---|
Nicole Diedrichs,et al,.A Highly Efficient Synthesis of Rocaglaols by a Novel α-Arylation of Ketones,.Eur. J. Org. Chem.9.2005,91731-1735. * |
说明书第21栏实施例I-6、第22栏实施例I-7、第1栏第47行至第2栏第48行、权利要求1. |
Also Published As
Publication number | Publication date |
---|---|
IL179257A (en) | 2013-02-28 |
US8030347B2 (en) | 2011-10-04 |
CA2567404A1 (en) | 2005-12-01 |
RU2006144710A (ru) | 2008-06-27 |
KR101215164B1 (ko) | 2012-12-24 |
RU2415847C2 (ru) | 2011-04-10 |
MXPA06013182A (es) | 2007-02-14 |
ZA200609444B (en) | 2008-01-30 |
BRPI0510403A (pt) | 2007-10-23 |
CN1989122A (zh) | 2007-06-27 |
WO2005113529A3 (de) | 2006-02-09 |
RU2415847C9 (ru) | 2011-08-10 |
WO2005113529A2 (de) | 2005-12-01 |
EP1751127A2 (de) | 2007-02-14 |
US20090018113A1 (en) | 2009-01-15 |
IL179257A0 (en) | 2007-03-08 |
AU2005245104B2 (en) | 2011-07-28 |
AU2005245104A1 (en) | 2005-12-01 |
KR20070011522A (ko) | 2007-01-24 |
CA2567404C (en) | 2014-04-01 |
JP2007538031A (ja) | 2007-12-27 |
DE102004024504A1 (de) | 2006-02-16 |
EP1751127B1 (de) | 2012-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1989122B (zh) | 新型环戊[b]苯并呋喃衍生物及其用途 | |
TWI790264B (zh) | 雜環化合物及其用途 | |
CN115192577B (zh) | Kras突变蛋白抑制剂 | |
CN101578273B (zh) | 作为akt蛋白激酶抑制剂的羟基化和甲氧基化的环戊二烯并[d]嘧啶 | |
CN113200981A (zh) | 作为sos1抑制剂的杂环化合物 | |
WO2022268230A1 (zh) | 作为kif18a抑制剂的化合物 | |
BG107355A (bg) | Нови полициклични съединения и тяхното използване | |
KR100818061B1 (ko) | 아미드 화합물 및 그의 용도 | |
CN101720318A (zh) | 用作Hsp90抑制剂的喹唑啉-肟衍生物 | |
CN108191861B (zh) | N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-反式-2,4-戊二烯酰胺 | |
CN109843872A (zh) | 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物 | |
JP2023533944A (ja) | 免疫調節剤 | |
EP1295878B1 (en) | Pyrazinone derivatives | |
EP2767538B1 (en) | Tetrandrine derivatives with substituted 5-carbon, preparation method and use thereof | |
WO2023280182A1 (zh) | 作为kat6抑制剂的化合物 | |
CN109678815B (zh) | N-苄基苯甲酰胺类衍生物及其制备方法与制药用途 | |
CN110407854B (zh) | 新的四环化合物 | |
CN107207444A (zh) | 二环化合物 | |
TW202138352A (zh) | 經取代之雙環及三環脲類及醯胺類、其類似物及使用其之方法 | |
WO2022122044A1 (zh) | 作为gls1抑制剂的杂环化合物 | |
CN113336774A (zh) | 作为trk抑制剂的取代的手性二芳基大环化合物 | |
CN109071503A (zh) | 用于抑制亲环素的化合物及其用途 | |
CN113264925A (zh) | 一种杂环化合物及其制备方法和用途 | |
JPH02289571A (ja) | 3―アルケニル―1―アザビシクロ[3.2.0]ヘプト―2―エン―2―カルボン酸誘導体およびその製造法、並びにそれを含む抗菌性薬剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: INTEC MED EXPLORE LIMITED LIABILITY COMPANY Free format text: FORMER OWNER: BAYER HEALTHCARE AG Effective date: 20070824 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20070824 Address after: Borussia Dortmund Applicant after: Bayer Healthcare AG Address before: Germany Leverkusen Applicant before: Bayer Healthcare AG |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1108885 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1108885 Country of ref document: HK |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130724 Termination date: 20140514 |